Q4 2019/20 Initiation

Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited VIVOTM non- invasive mapping 19/LO/03 Please Please 162140 257755 of Yes 03/07/2019 26 33 59 01/03/2019 05/05/2019 21/04/2019 15/05/2019 31/05/2019 31/05/2019 08 Select... Select... ventricula r arrhythmi a

A Pilot Study to exPlOre the exisTence and impact of 19/LO/07 FRAILTY Please Please 162141 264744 Yes 20/08/2019 31 11 42 01/04/2019 09/07/2019 16/07/2019 24/07/2019 09/08/2019 09/08/2019 84 in Select... Select... patients over the age of 70 undergoin g cardiac interventi ons Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

"Pressure- controlled Intermitte nt Coronary Sinus 19/SC/00 Occlusion Please Please 162142 259683 Yes 23/09/2019 40 12 52 01/04/2019 02/08/2019 16/07/2019 14/08/2019 11/09/2019 16/09/2019 50 (PiCSO) in Select... Select... Acute Myocardi al Infarction (PiCSO- AMI-I)" Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Randomiz ed, Double- blind, Placebo- Controlle d, Crossover , Dose 19/NW/0 Please Please 162143 260431 Escalation Yes 18/09/2019 8 36 44 15/04/2019 05/08/2019 14/06/2019 01/08/2019 13/08/2019 13/08/2019 181 Select... Select... Study of BLU-5937 in Subjects with Unexplain ed or Refractor y Chronic Cough Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase IIB, Randomis ed, Double- Blinded, Placebo- Controlle d Study of the Efficacy and Safety of 18/LO/00 Intramyoc Please NHS 162144 226737 Yes 16/03/2020 12 97 109 20/11/2017 28/11/2019 18/03/2018 03/12/2019 10/12/2019 10/12/2019 20 ardial Select... Provider Injection of Allogenei c Human Immunom odulatory Progenito r (iMP) cells in Patients Undergoi ng Coronary Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 3 study of the long- term safety of a triple combinati on therapy Yes - Date 19/NW/0 Please Please 162145 269907 of VX-445, Unavailab 37 28/08/2019 12/11/2019 06/11/2019 04/12/2019 19/12/2019 19/12/2019 540 Select... Select... tezacaftor le and ivacaftor in people with cystic fibrosis aged 12 and older Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 3 study of the efficacy, safety and the body?s effects on a triple combinati on Yes - Date 19/NW/0 Please Please 162146 269510 therapy Unavailab 31 12/02/2019 04/11/2019 04/11/2019 04/12/2019 05/12/2019 05/12/2019 506 Select... Select... of VX-445, le tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11 Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A study to evaluate the effectiven ess and safety of VX 445/Tezac aftor/Ivac aftor in people with 19/LO/13 Please Please 162147 268820 Cystic Yes 10/02/2020 40 63 103 19/06/2019 30/10/2019 29/10/2019 13/11/2019 09/12/2019 09/12/2019 18 Select... Select... Fibrosis who are heterozyg ous for the F508del mutation and a gating or residual function mutation Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

"Positiona l Therapy for Obstructi ve Sleep Apnoea: a Randomis ed Controlle 19/YH/02 Please Please 162148 252494 d Trial to Yes 30/10/2019 0 22 22 17/06/2019 08/10/2019 24/07/2019 08/10/2019 08/10/2019 08/10/2019 22 Select... Select... assess the effect on Health and Wellbeing in Older and Younger People." Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited FIRST-line support for Assistanc e in Breathing in Children (FIRST- ABC): A master protocol of two 19/EE/01 randomis Please Please 162149 260536 Yes 03/09/2019 0 11 11 04/06/2019 23/08/2019 26/07/2019 23/08/2019 23/08/2019 30/08/2019 85 ed trials Select... Select... to evaluate the non- inferiority of high flow nasal cannula (HFNC) versus continuou s positive airway pressure Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited "SPACE FOR COPD? delivered as a maintena nce program me on Pulmonar y Rehabilita tion 19/EM/02 discharge: Please Please 162150 262581 Yes 15/11/2019 13 17 30 19/08/2019 16/10/2019 10/10/2019 10/10/2019 29/10/2019 29/10/2019 67 a Select... Select... randomis ed controlled trial evaluatin g the long- term effects on exercise tolerance and mental wellbeing Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited Randomiz ed, Double- Blind, Placebo- Controlle d, Dose- Ranging, Efficacy and Safety Study with 19/EM/01 Inhaled Please NHS 162151 260487 Yes 27/02/2020 35 183 218 13/03/2019 24/07/2019 17/06/2019 27/08/2019 28/08/2019 28/08/2019 01 RVT-1601 Select... Provider for the Treatmen t of Persistent Cough in Patients with Idiopathic Pulmonar y Fibrosis (IPF): SCENIC Trial Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 2, Multicent er, Blinded, Sham Procedure- Controlle d Trial of Renal Denervati on by the 18/LO/20 Peregrine Please NHS 162152 250980 No 29 28/11/2018 05/09/2019 14/02/2019 24/09/2019 04/10/2019 04/10/2019 06 System Select... Provider Kit, in Subjects with Hypertens ion, in the Absence of Antihyper tensive Medicatio ns Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

Randomis ed Evaluatio 20/EE/01 n of Please Please 163700 281712 Yes 08/04/2020 12 8 20 19/03/2020 19/03/2020 17/03/2020 13/03/2020 31/03/2020 31/03/2020 01 COVID-19 Select... Select... Therapy (RECOVER Y) An open- label extension trial of the long- term safety of nintedani 18/EM/03 b in Please Please 163701 252018 Yes 04/06/2019 0 22 22 18/01/2019 13/05/2019 15/01/2019 13/05/2019 13/05/2019 03/06/2019 65 patients Select... Select... with Progressiv e Fibrosing Interstitia l Lung Disease (PF-ILD) Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A randomis ed, double- blind, placebo- controlled and parallel group trial to evaluate efficacy 19/LO/11 and Please NHS 163702 263830 No 129 28/06/2019 19/07/2019 05/11/2019 19/11/2019 25/11/2019 28/11/2019 67 safety of Select... Provider twice daily inhaled doses of BI 1265162 delivered by Respimat ? inhaler as add-on therapy to Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

EURO SHOCK Testing the value of novel strategy and its 18/EM/04 cost Please 163703 250403 No 151 18/03/2019 09/08/2019 04/03/2019 07/01/2020 07/01/2020 15/01/2020 Neither 06 efficacy in Select... order to improve the poor outcomes in Cardiogen ic Shock Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 2 Study of ABBV- 3067 Alone and in Combinati on with ABBV- 19/YH/03 Please NHS 163704 268446 2222 in No 160 17/09/2019 17/09/2019 31/10/2019 21/02/2020 24/02/2020 24/02/2020 01 Select... Provider Cystic Fibrosis Subjects Who Are Homozyg ous for the F508del Mutation Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

An explorato ry sub- study to protocol GLPG1690- CL-303 to assess lung function in 19/WA/0 Please Please 163705 269743 patients Yes 19/02/2020 126 28 154 10/07/2019 18/09/2019 04/11/2019 14/01/2020 22/01/2020 22/01/2020 277 Select... Select... with idiopathic pulmonar y fibrosis, using hyperpola rized xenon magnetic resonance imaging Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited GALACTIC- 1 - A randomiz ed, double- blind, multicent re, parallel, placebo controlled Phase 2b study in 19/LO/05 subjects Please NHS 163706 257627 Yes 08/01/2020 34 71 105 28/06/2019 25/09/2019 24/09/2019 24/09/2019 29/10/2019 29/10/2019 53 with Select... Provider idiopathic pulmonar y fibrosis (IPF) investigat ing the efficacy and safety of TD139, an inhaled galectin-3 inhibitor Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase 3 study of the long- term safety and efficacy of a triple combinati on therapy of VX-445, tezacaftor 19/LO/13 and Please NHS 163708 268821 Yes 17/04/2020 128 42 170 20/09/2019 30/10/2019 29/10/2019 02/12/2019 06/03/2020 06/03/2020 17 ivacaftor Select... Provider in people with cystic fibrosis aged 12 and older who have one copy of the F508del mutation and one copy of a Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A multicent er, randomiz ed, double- blind, placebo- controlled , parallel- group, group- sequentia 18/EE/03 l, Please NHS 163709 253601 No 50 09/12/2019 10/12/2019 25/03/2019 27/01/2020 29/01/2020 29/01/2020 90 adaptive, Select... Provider Phase 3 study with open- label extension period to assess the efficacy and safety of selexipag as an add- on to Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A phase 1/2a study to assess various doses of an ENaC inhibitor medicatio 18/NI/014 Please 163710 252483 n called No 21 31/10/2019 06/01/2020 11/12/2019 07/01/2020 27/01/2020 27/02/2020 Neither 5 Select... ION- 827359 in Healthy Volunteer s and People With Cystic Fibrosis A phase 1/2a study to assess various doses of an ENaC inhibitor medicatio 18/NI/014 Please 163710 252483 n called No 21 31/10/2019 06/01/2020 11/12/2019 07/01/2020 27/01/2020 27/02/2020 Neither 5 Select... ION- 827359 in Healthy Volunteer s and People Duration With Duration Duration between Research Integrate Cystic between between First Date Site Ethics d Fibrosis Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Pilot Study to exPlOre the exisTence and impact of 19/LO/07 FRAILTY in Please Please 167374 264744 Yes 20/08/2019 31 11 42 01/04/2019 09/07/2019 16/07/2019 24/07/2019 09/08/2019 09/08/2019 84 patients over Select... Select... the age of 70 undergoing cardiac interventions

"Pressure- controlled Intermittent Coronary Sinus 19/SC/00 Occlusion Please Please 167375 259683 Yes 23/09/2019 40 12 52 01/04/2019 02/08/2019 16/07/2019 14/08/2019 11/09/2019 16/09/2019 50 (PiCSO) in Select... Select... Acute Myocardial Infarction (PiCSO-AMI-I)" Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Randomized, Double-blind, Placebo- Controlled, Crossover, Dose 19/NW/0 Please Please 167376 260431 Escalation Yes 18/09/2019 8 36 44 15/04/2019 05/08/2019 14/06/2019 01/08/2019 13/08/2019 13/08/2019 181 Select... Select... Study of BLU- 5937 in Subjects with Unexplained or Refractory Chronic Cough Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase IIB, Randomised, Double- Blinded, Placebo- Controlled Study of the Efficacy and Safety of Intramyocardi al Injection of Allogeneic 18/LO/00 Human Please NHS 167377 226737 Yes 16/03/2020 12 97 109 20/11/2017 28/11/2019 18/03/2018 03/12/2019 10/12/2019 10/12/2019 20 Immunomodul Select... Provider atory Progenitor (iMP) cells in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. Protocol: CLX003-IMP-2- 170121 Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 3 study of the long-term safety of a triple combination Yes - Date 19/NW/0 Please Please 167378 269907 therapy of VX- Unavailab 37 28/08/2019 12/11/2019 06/11/2019 04/12/2019 19/12/2019 19/12/2019 540 Select... Select... 445, tezacaftor le and ivacaftor in people with cystic fibrosis aged 12 and older

A Phase 3 study of the efficacy, safety and the body?s effects on a triple Yes - Date 19/NW/0 combination Please Please 167379 269510 Unavailab 31 12/02/2019 04/11/2019 04/11/2019 04/12/2019 05/12/2019 05/12/2019 506 therapy of VX- Select... Select... le 445, tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11 Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A study to evaluate the effectiveness and safety of VX 445/Tezacafto r/Ivacaftor in people with 19/LO/13 Cystic Fibrosis Please Please 167380 268820 Yes 10/02/2020 40 63 103 19/06/2019 30/10/2019 29/10/2019 13/11/2019 09/12/2019 09/12/2019 18 who are Select... Select... heterozygous for the F508del mutation and a gating or residual function mutation

"Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled 19/YH/02 Please Please 167381 252494 Trial to assess Yes 30/10/2019 0 22 22 17/06/2019 08/10/2019 24/07/2019 08/10/2019 08/10/2019 08/10/2019 22 Select... Select... the effect on Health and Wellbeing in Older and Younger People." Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the 19/EE/018 non-inferiority Please Please 167382 260536 Yes 03/09/2019 0 11 11 04/06/2019 23/08/2019 26/07/2019 23/08/2019 23/08/2019 30/08/2019 5 of high flow Select... Select... nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non- invasive respiratory support in paediatric critical care Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

"SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation discharge: a 19/EM/02 Please Please 167383 262581 randomised Yes 15/11/2019 13 17 30 19/08/2019 16/10/2019 10/10/2019 10/10/2019 29/10/2019 29/10/2019 67 Select... Select... controlled trial evaluating the long-term effects on exercise tolerance and mental wellbeing" Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

Randomized, Double-Blind, Placebo- Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled 19/EM/01 Please NHS 167384 260487 RVT-1601 for Yes 27/02/2020 35 183 218 13/03/2019 24/07/2019 17/06/2019 27/08/2019 28/08/2019 28/08/2019 01 Select... Provider the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 2, Multicenter, Blinded, Sham Procedure- Controlled Trial of Renal Denervation by the 18/LO/20 Please NHS 167385 250980 Peregrine No 29 28/11/2018 05/09/2019 14/02/2019 24/09/2019 04/10/2019 04/10/2019 06 Select... Provider System Kit, in Subjects with Hypertension, in the Absence of Antihypertensi ve Medications Randomised Evaluation of 20/EE/010 Please Please 167386 281712 COVID-19 Yes 08/04/2020 12 8 20 19/03/2020 19/03/2020 17/03/2020 13/03/2020 31/03/2020 31/03/2020 1 Select... Select... Therapy (RECOVERY) Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A randomised, double-blind, placebo- controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled 19/LO/11 Please NHS 167387 263830 doses of BI No 129 28/06/2019 19/07/2019 05/11/2019 19/11/2019 25/11/2019 28/11/2019 67 Select... Provider 1265162 delivered by Respimat? inhaler as add- on therapy to standard of care over 4 weeks in patients with cystic fibrosis

18/EM/04 EURO SHOCK Please 167388 250403 No 151 18/03/2019 09/08/2019 04/03/2019 07/01/2020 07/01/2020 15/01/2020 Neither 06 Testing the Select... Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase 2 Study of ABBV- 3067 Alone and in Combination with ABBV- 19/YH/03 2222 in Cystic Please NHS 167389 268446 No 160 17/09/2019 17/09/2019 31/10/2019 21/02/2020 24/02/2020 24/02/2020 01 Fibrosis Select... Provider Subjects Who Are Homozygous for the F508del Mutation

An exploratory sub-study to protocol GLPG1690-CL- 303 to assess lung function in patients 19/WA/0 Please Please 167390 269743 with idiopathic Yes 19/02/2020 126 28 154 10/07/2019 18/09/2019 04/11/2019 14/01/2020 22/01/2020 22/01/2020 277 Select... Select... pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary 19/LO/05 fibrosis (IPF) Please NHS 167391 257627 Yes 08/01/2020 34 71 105 28/06/2019 25/09/2019 24/09/2019 24/09/2019 29/10/2019 29/10/2019 53 investigating Select... Provider the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

A Phase 3 study of the long-term safety and efficacy of a triple combination therapy of VX- 445, tezacaftor and ivacaftor 19/LO/13 in people with Please NHS 167392 268821 Yes 17/04/2020 128 42 170 20/09/2019 30/10/2019 29/10/2019 02/12/2019 06/03/2020 06/03/2020 17 cystic fibrosis Select... Provider aged 12 and older who have one copy of the F508del mutation and one copy of a gating or residual function mutation Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A multicenter, randomized, double-blind, placebo- controlled, parallel-group, group- sequential, adaptive, Phase 3 study with open- label extension 18/EE/039 period to Please NHS 167393 253601 No 50 09/12/2019 10/12/2019 25/03/2019 27/01/2020 29/01/2020 29/01/2020 0 assess the Select... Provider efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/rec urrent after surgical treatment Chronic 18/NI/014 A phase 1/2a Please 167394 252483 No 21 31/10/2019 06/01/2020 11/12/2019 07/01/2020 27/01/2020 27/02/2020 Neither 5 study to assess Select... Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited

Randomized, Embedded, Multifactorial, 18/LO/06 Adaptive Please 167401 237150 No 14 27/03/2020 31/03/2020 23/07/2018 06/04/2020 14/04/2020 14/04/2020 Neither 60 Platform trial Select... for Community- Acquired Pneumonia Ventilation Strategies in 20/HRA/1 COVID-19; Please 167402 282338 No 0 14/04/2020 17/04/2020 03/04/2020 17/04/2020 17/04/2020 17/04/2020 Neither 696 CPAP, High- Select... flow, and standard care Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date Site Date Site Reasons Participan Date of First Confirme HRA Date Site Non- Date Site Committe Research Selected Selected Date Site Date Site Date Site for delay Name of Trial t Participant d and Approval Confirmed Confirmat Ready To e Applicatio and Date and First Invited Selected Confirmed correspon Recruited Recruited First Date By Sponsor ion Status Start Reference n System Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase 3b randomised, placebo- controlled study of the efficacy and safety of a triple combination therapy of elexacaftor 20/NW/0 Please 167403 1003047 (VX-445), No 104 28/02/2020 14/05/2020 14/05/2020 18/05/2020 26/08/2020 27/08/2020 Neither 195 Select... tezacaftor and ivacaftor in people with cystic fibrosis aged 6 to 11 with one F508del mutation and one minimal function mutation Duration Duration Duration Research Integrate between between First between Ethics d Date Site Date Site Reasons Participan Date of First Date Site HRA Date Site Non- Date Site Committe Research Confirmed Selected Date Site Date Site Date Site for delay Name of Trial t Participant Selected Approval Confirmed By Confirmat Ready To e Applicatio and First and First Invited Selected Confirmed correspon Recruited Recruited and Date Date Sponsor ion Status Start Reference n System Participan Participan d to: ? Site Number Number t t Confirmed Recruited Recruited

A Phase IIB, Randomised, Double-Blinded, Placebo- Controlled Study of the Efficacy and Safety of Intramyocardial Injection of 18/LO/00 Allogeneic Human Please NHS 167404 226737 Yes 16/03/2020 12 97 109 20/11/2017 28/11/2019 18/03/2018 03/12/2019 10/12/2019 10/12/2019 20 Immunomodulatory Select... Provider Progenitor (iMP) cells in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. Protocol: CLX003-IMP-2-170121

A Phase 3 study of the long- term safety of a triple Yes - Date 19/NW/0 combination therapy of VX- Please Please 167405 269907 Unavailab 37 28/08/2019 12/11/2019 06/11/2019 04/12/2019 19/12/2019 19/12/2019 540 445, tezacaftor and ivacaftor Select... Select... le in people with cystic fibrosis aged 12 and older

A Phase 3 study of the efficacy, safety and the body?s effects on a triple Yes - Date 19/NW/0 Please Please 167406 269510 combination therapy of VX- Unavailab 31 12/02/2019 04/11/2019 04/11/2019 04/12/2019 05/12/2019 05/12/2019 506 Select... Select... 445, tezacaftor and ivacaftor le in children with cystic fibrosis aged 6 to 11

A study to evaluate the effectiveness and safety of VX 445/Tezacaftor/Ivacaftor 19/LO/13 in people with Cystic Fibrosis Please Please 167407 268820 Yes 10/02/2020 40 63 103 19/06/2019 30/10/2019 29/10/2019 13/11/2019 09/12/2019 09/12/2019 18 who are heterozygous for the Select... Select... F508del mutation and a gating or residual function mutation Duration Duration Duration Research Integrate between between First between Ethics d Date Site Date Site Reasons Participan Date of First Date Site HRA Date Site Non- Date Site Committe Research Confirmed Selected Date Site Date Site Date Site for delay Name of Trial t Participant Selected Approval Confirmed By Confirmat Ready To e Applicatio and First and First Invited Selected Confirmed correspon Recruited Recruited and Date Date Sponsor ion Status Start Reference n System Participan Participan d to: ? Site Number Number t t Confirmed Recruited Recruited

"Positional Therapy for Obstructive Sleep Apnoea: a 19/YH/02 Randomised Controlled Trial Please Please 167408 252494 Yes 30/10/2019 0 22 22 17/06/2019 08/10/2019 24/07/2019 08/10/2019 08/10/2019 08/10/2019 22 to assess the effect on Health Select... Select... and Wellbeing in Older and Younger People."

"SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation 19/EM/02 discharge: a randomised Please Please 167409 262581 Yes 15/11/2019 13 17 30 19/08/2019 16/10/2019 10/10/2019 10/10/2019 29/10/2019 29/10/2019 67 controlled trial evaluating the Select... Select... long-term effects on exercise tolerance and mental wellbeing"

Randomised Evaluation of 20/EE/01 Please Please 167410 281712 COVID-19 Therapy Yes 08/04/2020 12 8 20 19/03/2020 19/03/2020 17/03/2020 13/03/2020 31/03/2020 31/03/2020 01 Select... Select... (RECOVERY)

A Phase 3 study of the long- term safety and efficacy of a triple combination therapy of VX-445, tezacaftor and 19/LO/13 ivacaftor in people with cystic Please NHS 167411 268821 Yes 17/04/2020 128 42 170 20/09/2019 30/10/2019 29/10/2019 02/12/2019 06/03/2020 06/03/2020 17 fibrosis aged 12 and older Select... Provider who have one copy of the F508del mutation and one copy of a gating or residual function mutation Duration Duration Duration Research Integrate between between First between Ethics d Date Site Date Site Reasons Participan Date of First Date Site HRA Date Site Non- Date Site Committe Research Confirmed Selected Date Site Date Site Date Site for delay Name of Trial t Participant Selected Approval Confirmed By Confirmat Ready To e Applicatio and First and First Invited Selected Confirmed correspon Recruited Recruited and Date Date Sponsor ion Status Start Reference n System Participan Participan d to: ? Site Number Number t t Confirmed Recruited Recruited

A multicenter, randomized, double-blind, placebo- controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open- label extension period to 18/EE/03 assess the efficacy and safety Please NHS 167412 253601 No 50 09/12/2019 10/12/2019 25/03/2019 27/01/2020 29/01/2020 29/01/2020 90 of selexipag as an add-on to Select... Provider standard of care therapy in subjects with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.

18/NI/014 A phase 1/2a study to assess Please 167413 252483 No 21 31/10/2019 06/01/2020 11/12/2019 07/01/2020 27/01/2020 27/02/2020 Neither 5 various doses of an ENaC Select...

Randomized, Embedded, 18/LO/06 Multifactorial, Adaptive Please 167414 237150 No 14 27/03/2020 31/03/2020 23/07/2018 06/04/2020 14/04/2020 14/04/2020 Neither 60 Platform trial for Community- Select... Acquired Pneumonia

Ventilation Strategies in 20/HRA/1 Please 167415 282338 COVID-19; CPAP, High-flow, No 0 14/04/2020 17/04/2020 03/04/2020 17/04/2020 17/04/2020 17/04/2020 Neither 696 Select... and standard care

A Phase 3b randomised, placebo-controlled study of the efficacy and safety of a triple combination therapy of 20/NW/0 elexacaftor (VX-445), Please 167416 1003047 No 104 28/02/2020 14/05/2020 14/05/2020 18/05/2020 26/08/2020 27/08/2020 Neither 195 tezacaftor and ivacaftor in Select... people with cystic fibrosis aged 6 to 11 with one F508del mutation and one minimal function mutation Duration Duration Duration Research Integrate between between First between Ethics d Date Site Date Site Reasons Participan Date of First Date Site HRA Date Site Non- Date Site Committe Research Confirmed Selected Date Site Date Site Date Site for delay Name of Trial t Participant Selected Approval Confirmed By Confirmat Ready To e Applicatio and First and First Invited Selected Confirmed correspon Recruited Recruited and Date Date Sponsor ion Status Start Reference n System Participan Participan d to: ? Site Number Number t t Confirmed Recruited Recruited

Breathe Plus: Testing the feasibility of a comprehensive 19/LO/14 geriatric assessment for Please 167417 268185 Yes 25/02/2020 69 49 118 23/10/2019 30/10/2019 23/10/2019 07/01/2020 07/01/2020 12/02/2020 Sponsor 02 people with COPD and frailty Select... starting pulmonary rehabilitation Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with Recruitme 18/LO/05 idiopathic pulmonary Number Date 46044 239042 1 1 18/09/2019 1 23/07/2019 1 nt 03 fibrosis (IPF) on no Agreed Agreed Finished background anti- fibrotic (Part 1) and safety and tolerability of BI 1015550 on top of Nintedanib and Pir Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

The?Effects?of?Inorga nic?Nitrite?on?cardiac ?and?skeletal?muscle: Recruitme 12/SS/00 ?Physiology, Number Date 46045 87162 16 16 28/06/2019 18 28/06/2019 18 nt 37 Pharmacology, and Agreed Agreed Finished Therapeutic?Potential in patients with Chronic Heart Failure Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Recruitme 17/LO/10 Number Date 46046 228921 Treatment in Subjects 3 3 24/11/2018 5 24/08/2019 5 nt 88 Agreed Agreed With Cystic Fibrosis Finished Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

The?CELEB?trial:?Com parative?Effectiveness ?of?Lung?volume?red uction?surgery?for?E Recruitme 16/LO/02 Range Date 46047 188120 mphysema?and?Bronc 30 40 28/08/2019 30 28/08/2019 30 nt 86 Agreed Agreed hoscopic Finished lung?volume?reductio n?with?valve?placeme nt

A Phase 2, Randomized, Double- blind, Controlled Study to Evaluate the Recruitme 19/NW/0 Safety and Efficacy of Number Date 46048 249432 1 1 31/08/2019 3 05/09/2019 3 nt 026 VX-121 Combination Agreed Agreed Finished Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

An Open-label, non- controlled, multicentre, Pilot clinical Trial of Inhaled Recruitme 18/LO/02 Molgramostim in Number Date 46049 238305 1 1 25/10/2019 2 25/10/2019 2 nt 95 subjects with Agreed Agreed Finished Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection - OPTIMA Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A prospective, randomized, international, multicenter, double- arm, controlled, open- label study of Recruitme 16/WS/02 Riociguat in patients Number Date 46050 213242 2 2 31/10/2019 1 31/10/2019 1 nt 23 with pulmonary Agreed Agreed Finished arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without en Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A randomised, double- blind (sponsor unblind), placebo- controlled, multi- centred phase IIa study to evaluate the Recruitme 18/EE/00 Number Date 46051 235968 safety and efficacy of 6 6 31/07/2019 8 06/12/2019 8 nt 92 Agreed Agreed 13 weeks of once daily Finished oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Phase 1/2, Drug- Drug Interaction Study of FDL169 and FDL176 Withdraw 18/NI/017 in Healthy Subjects Number Date 46052 253727 2 2 30/12/2019 0 10/12/2019 0 n By 8 and in Cystic Fibrosis Agreed Agreed Sponsor Subjects Homozygous for the F508del-CFTR Mutation

Clinical Investigation Withdraw 18/LO/09 of the VytronUS Number Date 46053 230460 15 15 31/12/2019 6 06/09/2019 6 n By 67 Ablation System for Agreed Agreed Sponsor Treatment

Evaluation of patient Recruitme 17/EE/05 experiences of Inhaled Number Date 47812 237814 10 10 15/05/2019 5 15/05/2019 5 nt 17 Iloprost using the Agreed Agreed Finished Breelib nebulizer Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

Utilizing Novel Dipole Density Capabilities to Objectively Visualize Recruitme 18/NE/00 Number Date 47813 239296 the Etiology of 10 10 01/02/2019 9 18/06/2019 9 nt 33 Agreed Agreed Recurrent Atrial Finished Fibrillation Following a Failed AF Ablation Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Multicenter, Open- label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Recruitme 18/EE/02 Number Date 47814 248137 Reduce Oral 10 10 24/06/2019 8 24/06/2019 8 nt 35 Agreed Agreed Corticosteroid Use in Finished Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long acting ?

A randomised, controlled trial of the Recruitme 17/SC/06 Number Date 47815 217496 use of a dedicated 5 5 01/05/2019 12 28/06/2019 12 nt 07 Agreed Agreed ballooned intercostal Finished drain Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

AN OPEN-LABEL, NON- CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED Withdraw 18/SW/01 MOLGRAMOSTIM IN Number Date 47816 241436 4 4 21/06/2021 4 25/07/2019 4 n By 15 AUTOIMMUNE Agreed Agreed Sponsor PULMONARY ALVEOLAR PROTEINOSIS PATIENTS- IMPALA EXTENSION Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

CQAW039B2201: A multicenter, open- label, 8 day treatment study to assess the pharmacokinetics, Withdraw 19/NW/0 Number Date 47817 264789 safety and tolerability 1 1 30/06/2020 0 16/12/2019 0 n By 394 Agreed Agreed of fevipiprant Sponsor delivered via a once daily chewable tablet in children aged 6 to <12 years with asthma Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Randomized, Double- Blind, Placebo- Controlled, Parallel- Group, Multi-Center Study to Assess the Efficacy, Safety and Withdraw 17/NW/0 Number Date 47818 233267 Tolerability, and 3 3 31/12/2019 0 31/12/2019 0 n By 678 Agreed Agreed Pharmacokinetics of Sponsor INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectas Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Phase 3, Randomized, Double- blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Recruitme 19/LO/13 Therapy in Subjects Number Date 47819 268820 3 3 01/03/2020 4 01/03/2020 4 nt 18 With Cystic Fibrosis Agreed Agreed Finished Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A randomised controlled trial of very early versus delayed 18/EE/02 angiography +/- Number Date Withdraw 47820 233921 25 25 30/09/2020 0 19/03/2020 0 22 intervention on Agreed Agreed n By Host outcomes in patients with non ST-elevation myocardial infarction Minimum Maximum Total Number Number Number Research Of Of Total Integrated Target Target Of Ethics Patients Patients Date Agreed Number Reason Research Number Date To Patients Date That The Committe Agreed Agreed to recruit Of Study For d Applicatio Name of Trial Of Recruit Recruited Trial Closed To e (Enter (Enter target number Participan Closure Of n System Patients Patients At The Recruitment Reference Same In Same In of patients ts Trial Number Agreed? Agreed? Agreed Number Both If Both If Recruited Target Only One Only One Date Number) Number) Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)

Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with idiopathic pulmonary Recruitme 18/LO/05 Number Date 48419 239042 fibrosis (IPF) on no background anti- 1 1 18/09/2019 1 23/07/2019 1 nt 03 Agreed Agreed fibrotic (Part 1) and safety and tolerability Finished of BI 1015550 on top of Nintedanib and Pir

A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Recruitme 17/LO/10 Number Date 48420 228921 Treatment in Subjects With Cystic Fibrosis 3 3 24/11/2018 5 24/08/2019 5 nt 88 Agreed Agreed Who Are Less Than 24 Months of Age at Finished Treatment Initiation and Have a CFTR Gating Mutation

The?CELEB?trial:?Comparative?Effectiven ess?of?Lung?volume?reduction?surgery?f Recruitme 16/LO/02 Range Date 48421 188120 or?Emphysema?and?Bronchoscopic 30 40 28/08/2019 30 28/08/2019 30 nt 86 Agreed Agreed lung?volume?reduction?with?valve?place Finished ment Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety Recruitme 19/NW/0 Number Date 48422 249432 and Efficacy of VX-121 Combination 1 1 31/08/2019 3 05/09/2019 3 nt 026 Agreed Agreed Therapy in Subjects Aged 18 Years and Finished Older With Cystic Fibrosis

An Open-label, non-controlled, multicentre, Pilot clinical Trial of Inhaled Recruitme 18/LO/02 Number Date 48423 238305 Molgramostim in subjects with Antibiotic- 1 1 25/10/2019 2 25/10/2019 2 nt 95 Agreed Agreed resistant non-tuberculosis mycobacterial Finished (NTM) infection - OPTIMA

A prospective, randomized, international, multicenter, double-arm, controlled, open- label study of Riociguat in patients with Recruitme 16/WS/02 Number Date 48424 213242 pulmonary arterial hypertension (PAH) 2 2 31/10/2019 1 31/10/2019 1 nt 23 Agreed Agreed who are on a stable dose of Finished phosphodiesterase-5 inhibitors (PDE-5i) with or without en Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A randomised, double-blind (sponsor unblind), placebo-controlled, multi- centred phase IIa study to evaluate the Recruitme 18/EE/00 Number Date 48425 235968 safety and efficacy of 13 weeks of once 6 6 31/07/2019 8 06/12/2019 8 nt 92 Agreed Agreed daily oral dosing of the selective androgen Finished receptor modulator (SARM) GSK2881078 in older men and A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects Withdraw 18/NI/017 Number Date 48426 253727 and in Cystic Fibrosis Subjects 2 2 30/12/2019 0 10/12/2019 0 n By 8 Agreed Agreed Homozygous for the F508del-CFTR Sponsor Mutation Withdraw 18/LO/09 Clinical Investigation of the VytronUS Number Date 48427 230460 15 15 31/12/2019 6 06/09/2019 6 n By 67 Ablation System for Treatment Agreed Agreed Sponsor AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF Withdraw 18/SW/01 INHALED MOLGRAMOSTIM IN Number Date 48428 241436 4 4 21/06/2021 4 25/07/2019 4 n By 15 AUTOIMMUNE PULMONARY ALVEOLAR Agreed Agreed Sponsor PROTEINOSIS PATIENTS- IMPALA EXTENSION Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)

CQAW039B2201: A multicenter, open- label, 8 day treatment study to assess the Withdraw 19/NW/0 pharmacokinetics, safety and tolerability Number Date 48429 264789 1 1 30/06/2020 0 16/12/2019 0 n By 394 of fevipiprant delivered via a once daily Agreed Agreed Sponsor chewable tablet in children aged 6 to <12 years with asthma

A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Withdraw 17/NW/0 Number Date 48430 233267 Tolerability, and Pharmacokinetics of 3 3 31/12/2019 0 31/12/2019 0 n By 678 Agreed Agreed INS1007 Administered Once Daily for 24 Sponsor Weeks in Subjects with Non-Cystic Fibrosis Bronchiectas

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Recruitme 19/LO/13 Number Date 48431 268820 Therapy in Subjects With Cystic Fibrosis 3 3 01/03/2020 4 01/03/2020 4 nt 18 Agreed Agreed Who Are Heterozygous for the F508del Finished Mutation and a Gating or Residual Function Mutation (F/G and Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)

A randomised controlled trial of very early 18/EE/02 versus delayed angiography +/- Number Date Withdraw 48432 233921 25 25 30/09/2020 0 19/03/2020 0 22 intervention on outcomes in patients with Agreed Agreed n By Host non ST-elevation myocardial infarction

A Randomized, Double-blind, Placebo- Recruitme 19/NW/0 Controlled, Crossover, Dose Escalation Number Date 48437 260431 5 5 31/01/2020 3 31/03/2020 3 nt 181 Study of BLU-5937 in Subjects with Agreed Agreed Finished Unexplained or Refractory Chronic Cough

IDL-2965 – A Phase I, Randomized, Double- blind, Placebo-controlled, Single and Recruitme 19/NW/0 Multiple Oral Dose, Safety, Tolerability, Number Date 48438 253853 6 6 01/02/2020 3 03/05/2020 3 nt 001 and Pharmacokinetic Study in Healthy Agreed Agreed Finished Subjects and Subjects with Idiopathic Pulmonary Fibrosis

A phase 1/2a study to assess various Withdraw 18/NI/014 doses of an ENaC inhibitor medication Number Date 48439 252483 3 3 31/03/2020 0 12/05/2020 0 n By 5 called ION-827359 in Healthy Volunteers Agreed Agreed Sponsor and People With Cystic Fibrosis Minimum Maximum Total Number Number Number Research Integrate Of Of Total Target Target Date Agreed Of Ethics d Patients Patients Date That Number Reason Number Date To to recruit Patients Committe Research Agreed Agreed The Trial Of Study For Name of Trial Of Recruit target Recruited e Applicatio (Enter (Enter Closed To Participan Closure Patients Patients number of At The Reference n System Same In Same In Recruitment ts Of Trial Agreed? Agreed? patients Agreed Number Number Both If Both If Recruited Target Only One Only One Date Number) Number)